In the wake of the 21st Century Cures Act’s passage, the use and evaluation of comparative effectiveness research (CER) by health care decision-makers is expected to increase. National Pharmaceutical Council (NPC) Chief Science Officer and Executive Vice President Robert Dubois, MD, PhD, will address how CER is being used by health care decision-makers as moderator of a panel on “Comparative Effectiveness: State of the Art and Stakeholder Perspectives” at the Drug Information Association 2017 Annual Meeting on Tuesday, June 20, at 2 p.m. Dr. Dubois and panelists will review key areas where multiple stakeholders are converging around real-world evidence for effectiveness, safety and value, and describe what roles the FDA and other regulators can (and should) play.
Understanding how treatments work in the real world is an important and complex task to guide care in real-world, clinical practice environments. CER can be used to help patients get the right treatments appropriate for their unique circumstances. NPC has been playing a leading role in encouraging the use of high-quality methodology and standards to conduct real-world research and helping decision-makers understand how to evaluate and use real-world evidence, including the use of CER to accomplish these goals. In his comments, Dr. Dubois will highlight NPC's work to explore the effective use of CER in health care decision-making and real-world evidence issues important to payers.
Dr. Dubois will be joined on the panel by David Thompson, PhD, senior vice president of real-world evidence and insights at InVentiv Health; and Jean Slutsky, PA, MSPH, chief engagement and dissemination officer at the Patient-Centered Outcomes Research Institute (PCORI).
Be sure to make this panel part of your agenda at DIA, and check out NPC's related resources to learn more about CER.